Keel Point’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $465K | Sell |
16,556
-3,733
| -18% | -$99.4K | 0.03% | 277 |
|
|
2025
Q4 | $505K | Buy |
20,289
+2,034
| +11% | +$51.3K | 0.03% | 298 |
|
|
2025
Q3 | $465K | Buy |
18,255
+3,093
| +20% | +$76.3K | 0.03% | 318 |
|
|
2025
Q2 | $368K | Buy |
15,162
+4,238
| +39% | +$98.8K | 0.02% | 364 |
|
|
2025
Q1 | $277K | Buy |
10,924
+2,911
| +36% | +$76.2K | 0.02% | 364 |
|
|
2024
Q4 | $213K | Sell |
8,013
-6,659
| -45% | -$181K | 0.02% | 401 |
|
|
2024
Q3 | $425K | Buy |
14,672
+503
| +4% | +$14.7K | 0.04% | 266 |
|
|
2024
Q2 | $409K | Buy |
+14,169
| New | +$390K | 0.04% | 272 |
|
|
2024
Q1 | – | Sell |
-7,152
| Closed | -$206K | – | 389 |
|
|
2023
Q4 | $206K | Buy |
+7,152
| New | +$216K | 0.02% | 330 |
|
|
2023
Q3 | – | Sell |
-9,066
| Closed | -$333K | – | 329 |
|
|
2023
Q2 | $333K | Buy |
9,066
+1,453
| +19% | +$56.6K | 0.04% | 236 |
|
|
2023
Q1 | $311K | Sell |
7,613
-2,165
| -22% | -$93.5K | 0.04% | 219 |
|
|
2022
Q4 | $501K | Sell |
9,778
-1,108
| -10% | -$53.1K | 0.08% | 161 |
|
|
2022
Q3 | $476K | Buy |
10,886
+182
| +2% | +$8.84K | 0.08% | 145 |
|
|
2022
Q2 | $535K | Buy |
10,704
+936
| +10% | +$47.7K | 0.08% | 134 |
|
|
2022
Q1 | $506K | Buy |
9,768
+2,275
| +30% | +$118K | 0.08% | 149 |
|
|
2021
Q4 | $442K | Buy |
7,493
+532
| +8% | +$26.4K | 0.05% | 165 |
|
|
2021
Q3 | $299K | Buy |
+6,961
| New | +$308K | 0.04% | 196 |
|
|
2021
Q2 | – | Sell |
-6,000
| Closed | -$217K | – | 303 |
|
|
2021
Q1 | $217K | Buy |
+6,000
| New | +$213K | 0.02% | 252 |
|
|
2020
Q2 | – | Sell |
-8,141
| Closed | -$252K | – | 204 |
|
|
2020
Q1 | $252K | Buy |
8,141
+103
| +1% | +$3.51K | 0.03% | 149 |
|
|
2019
Q4 | $299K | Buy |
8,038
+847
| +12% | +$30.2K | 0.03% | 157 |
|
|
2019
Q3 | $245K | Buy |
7,191
+5
| +0.1% | +$182 | 0.03% | 159 |
|
|
2019
Q2 | $295K | Sell |
7,186
-105
| -1% | -$4.17K | 0.03% | 157 |
|
|
2019
Q1 | $294K | Sell |
7,291
-2,852
| -28% | -$114K | 0.03% | 155 |
|
|
2018
Q4 | $420K | Sell |
10,143
-1,392
| -12% | -$57.8K | 0.06% | 133 |
|
|
2018
Q3 | $482K | Sell |
11,535
-575
| -5% | -$22.1K | 0.06% | 101 |
|
|
2018
Q2 | $417K | Buy |
12,110
+109
| +0.9% | +$3.73K | 0.06% | 98 |
|
|
2018
Q1 | $404K | Sell |
12,001
-213
| -2% | -$7.32K | 0.06% | 105 |
|
|
2017
Q4 | $420K | Sell |
12,214
-5,524
| -31% | -$188K | 0.06% | 108 |
|
|
2017
Q3 | $601K | Sell |
17,738
-2,061
| -10% | -$66.2K | 0.09% | 92 |
|
|
2017
Q2 | $631K | Sell |
19,799
-51
| -0.3% | -$1.61K | 0.13% | 80 |
|
|
2017
Q1 | $644K | Sell |
19,850
-245
| -1% | -$7.72K | 0.13% | 77 |
|
|
2016
Q4 | $619K | Sell |
20,095
-4,897
| -20% | -$149K | 0.14% | 74 |
|
|
2016
Q3 | $803K | Buy |
24,992
+10,622
| +74% | +$355K | 0.31% | 52 |
|
|
2016
Q2 | $480K | Buy |
14,370
+3
| +0% | +$96 | 0.21% | 81 |
|
|
2016
Q1 | $404K | Sell |
14,367
-1,611
| -10% | -$46K | 0.2% | 85 |
|
|
2015
Q4 | $489K | Sell |
15,978
-226
| -1% | -$7.11K | 0.26% | 74 |
|
|
2015
Q3 | $483K | Sell |
16,204
-10,571
| -39% | -$339K | 0.27% | 61 |
|
|
2015
Q2 | $868K | Buy |
26,775
+1,302
| +5% | +$42.4K | 0.41% | 40 |
|
|
2015
Q1 | $841K | Buy |
+25,473
| New | +$810K | 0.42% | 40 |
|
Other funds holding PFE
VCM
VPM
Keel Point's PFE Position: Q1 2026 in Review
Keel Point reduced its Pfizer (PFE) stake by 18% in Q1 2026, selling an estimated $99.4K and leaving 16,556 shares worth $465K. The position accounts for 0.03% of the portfolio, ranked #277.
Keel Point first reported a position in PFE in Q1 2015 and has held it in 39 quarters since. The position peaked at $868K in Q2 2015. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Keel Point held 16,556 shares of Pfizer worth $465K as of Q1 2026.
- Keel Point sold 3,733 Pfizer shares in Q1 2026, an estimated $99.4K.
- Pfizer made up 0.03% of Keel Point's portfolio in Q1 2026, its #277 holding.
- Keel Point first reported a position in Pfizer in Q1 2015 and has held it in 39 quarters since.
- Keel Point's Pfizer position peaked at $868K in Q2 2015.
- 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Keel Point's 13F filing for Q1 2026, filed 1 Jun 2026.